PD 166285
- Product NamePD 166285
- CAS212391-63-4
- CBNumberCB91873310
- MFC26H29Cl4N5O2
- MW585.37
- MDL NumberMFCD18086890
- MOL File212391-63-4.mol
Chemical Properties
Melting point | 239-242?C |
storage temp. | Desiccate at RT |
solubility | DMSO, Methanol |
form | Pale yellow solid |
color | Yellow |
Stability | Hygroscopic |
PD 166285 Price
Product number | Packaging | Price | Product description | Buy |
---|---|---|---|---|
Sigma-Aldrich 513028 | 5mg | $216 | PD 166285 - CAS 212391-63-4 - Calbiochem<br />A cell-permeable, orally bioavailable, ATP-competitive, broad-spectrum tyrosine kinase inhibitor that suppresses angiogenesis both in vitro and in vivo. |
Buy |
Tocris 3785 | 1 | $118 | PD166285dihydrochloride ≥99%(HPLC) |
Buy |
Usbiological 019157 | 5mg | $460 | PD-166285 |
Buy |
Usbiological 286681 | 2mg | $460 | PD 166285 |
Buy |
TRC P217500 | 25mg | $565 | PD-166285 |
Buy |
PD 166285 Chemical Properties,Usage,Production
Chemical Properties
Yellow SolidUses
A broad-spectrum receptor tyrosine kinase (RTK) inhibitor which shows anti-angiogenic activity and anti-tumor efficacy in combination with photodynamic therapy (PDT).General Description
A cell-permeable, orally bioavailable, ATP-competitive, broad-spectrum tyrosine kinase inhibitor (IC50 against against c-Src, Wee1, FGFR-1, Myt1, EGFR, and PDGFRβ = 8.4, 24, 39.3, 72, 87.5 and 98.3 nM, respectively) that suppresses angiogenesis both in vitro (max inhibition dose at 100 nM in HUVEC microcapillary formation assays) and in vivo (max inhibition achieved via 5 mg/kg p.o. in murine Matrigel plug angiogenesis assays), while exhibiting much reduced potency against Chk1, MAPK, and PKC (IC50 = 3.4, 5, and 22.7 μM, respectively) and little activity toward IRTK and Cdk4/D1 even at concentrations as high as 50 μM. Shown to effectively block PDGF-, EGF-, and bFGF-stimulated receptor phosphorylations (IC50 = 6.5, 1600, and 97.3 nM, respectively) and other cellular responses in rat aortic smooth muscle cells. Inhibition of cellular Wee1 activity by 500 nM PD 166285 in combination with 50 ng/ml nocodazole (Cat. No. 487928) treatment is also reported to result in a blockage of radiation-induced Cdc2 phosphorylation on Tyr15 and Thr14 in 7 human cancer cells and specifically demonstrated to sensatize PA-1 cultures to radiation-induced cell death in a p53-dependent manner.Biological Activity
Potent inhibitor of the tyrosine kinases c-Src, fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor β (PDGFR β ) (IC 50 values are 8.4, 39.3 and 98.3 nM respectively). Also inhibits the checkpoint kinases Wee1 and Myt1; abolishes Cdc2 phosphorylation in numerous tumor cell lines and abrogates the G 2 checkpoint.storage
Desiccate at RTPreparation Products And Raw materials
PD 166285 Supplier
Global(70)Suppliers
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
+undefined-21-51877795 | ivan@atkchemical.com | China | 32480 | 60 | |
+86-0371-86658258 15093356674; |
factory@coreychem.com | China | 29826 | 58 | |
+86-029-89586680 +86-18192503167 |
1026@dideu.com | China | 9320 | 58 | |
+86-29-89586680 +86-15129568250 |
1026@dideu.com | China | 29220 | 58 | |
+8615056975894 | shawn@hirisunpharm.com | CHINA | 9923 | 58 | |
+86-852-30606658 | market18@leapchem.com | China | 24738 | 58 | |
+undefined18051384581 | sales@chemhifuture.com | China | 3136 | 58 | |
+1-781-999-5354 | support@targetmol.com | United States | 19973 | 58 | |
+8618327326525 | masar@topule.com | China | 8474 | 58 | |
+86-18341751992 +86-15382112998 |
757984502@qq.com | China | 892 | 58 |
View Lastest Price from PD 166285 manufacturers
212391-63-4, PD 166285Related Search
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine